DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Phase 1

Completed

Conditions: Neoplasms by Site

Interventions: Biological: nivolumab
Drug: rHuPH20

First Posted Date: 2018-09-04

Last Posted Date: 2025-02-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 139

Registration Number: NCT03656718

Locations: 🇺🇸
Local Institution - 0012, Eugene, Oregon, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Local Institution - 0011, Tyler, Texas, United States

and more 33 locations

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

Completed

Conditions: Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2018-08-23

Last Posted Date: 2024-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1056

Registration Number: NCT03644498

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Phase 1

Completed

Conditions: Cardiac Failure
Myocardial Failure

Interventions: Drug: BMS-986224

First Posted Date: 2018-08-17

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT03634969

Locations: 🇺🇸
Prism Research, Saint Paul, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Other: Placebo

First Posted Date: 2018-08-17

Last Posted Date: 2020-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT03634995

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: NKTR-214
Biological: Nivolumab

First Posted Date: 2018-08-17

Last Posted Date: 2025-04-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 783

Registration Number: NCT03635983

Locations: 🇺🇸
Local Institution - 0187, Tucson, Arizona, United States
🇺🇸
Local Institution - 0001, Houston, Texas, United States
🇺🇸
Local Institution - 0064, Fairfax, Virginia, United States

and more 161 locations

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Other: Placebo
Drug: BMS-986165
Drug: Apremilast

First Posted Date: 2018-08-09

Last Posted Date: 2023-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 666

Registration Number: NCT03624127

Locations: 🇺🇸
Keck School of Medicine, Los Angeles, California, United States
🇯🇵
Sapporo Skin Clinic, Sapporo, Hokkaido, Japan
🇵🇱
DermoDent - Centrum Medyczne Czajkowscy, Osielsko, Poland

and more 150 locations

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Apremilast

First Posted Date: 2018-08-02

Last Posted Date: 2022-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1020

Registration Number: NCT03611751

Locations: 🇺🇸
Interspond - Savin Medical Group, Miami Lakes, Florida, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 195 locations

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Phase 2

Terminated

Conditions: Granulomatous Colitis
Crohn's Enteritis
Crohn's Disease
Granulomatous Enteritis

Interventions: Drug: BMS-986165
Other: Placebo

First Posted Date: 2018-07-26

Last Posted Date: 2024-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 239

Registration Number: NCT03599622

Locations: 🇺🇸
Local Institution - 0319, Chicago, Illinois, United States
🇺🇸
Local Institution - 0232, Miami, Florida, United States
🇺🇸
Local Institution - 0011, Las Vegas, Nevada, United States

and more 254 locations

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Completed

Conditions: Pulmonary Thromboembolism
Pulmonary Embolism (PE)

Interventions: Other: Non-Interventional

First Posted Date: 2018-07-23

Last Posted Date: 2022-05-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 660

Registration Number: NCT03595891

Locations: 🇬🇧
Local Institution, Cardiff, United Kingdom

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Completed

Conditions: Kidney Cancer
Renal Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2018-06-26

Last Posted Date: 2022-10-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 212

Registration Number: NCT03568435

Locations: 🇯🇵
Local Institution - 0001, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy